There will be an estimated 63,00 new cases of cancers of the kidney and renal pelvis in 2016 and about 14,000 deaths. Kidney cancer can affect both adults and children. In adults, when metastatic, kidney cancer remains largely incurable. Kidney cancer in children, known as Wilms tumor, is curable in most patients, but the treatment often leaves life-long sequelae. SPORE programs in kidney cancer address both adult and pediatric cancer and span a wide array of topics from the molecular genetics of the disease to novel treatment approaches, such as immunotherapies. The SPOREs in kidney cancer foster collaborations among experts in renal cancer in the United States and abroad, generating new resources and research opportunities for the scientific community.
David F. McDermott, M.D. [Click Here]
Beth Israel Deaconess Cancer Center/Dana-Farber/Harvard Cancer Center
Director, Biologic Therapy and Cutaneous Oncology Program
Division of Hematology/Oncology
375 Longwood Ave.
Masco Building, Room 412
Boston, MA 02215
William G. Kaelin, Jr., M.D.
Professor of Medicine
Dana-Farber Cancer Institute and Harvard Medical School
Howard Hughes Medical Institute
450 Brookline Avenue, Mayer 457
Boston, MA 02215 USA
For more information on this specific SPORE’s institution, please visit:
James Brugarolas, M.D., Ph.D. [Click Here]
Department of Internal Medicine, Oncology Division
Department of Developmental Biology
University of Texas Southwestern Medical Center
5323 Harry Hines Blvd.
Dallas, TX 75390-9133